Giving kids with early puberty a certain medicine doesn't seem to change their blood sugar, cholesterol, thyroid levels, testosterone, or bone strength during treatment.

From: The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis

Strongly supported

Multiple high-quality studies back this claim.

39
Pro
0
Against
correlational
1 study

Not medical advice. For informational purposes only. Always consult a healthcare professional.

What this claim means

Giving kids with early puberty a certain medicine doesn't seem to change their blood sugar, cholesterol, thyroid levels, testosterone, or bone strength during treatment.

See the technical phrasing

Treatment with gonadotropin-releasing hormone analog (GnRHa) in children with central precocious puberty is not associated with statistically significant changes in insulin sensitivity (HOMA-IR), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), testosterone (T), or bone mineral density (BMD) over the treatment period.

What the research says

Supports

1 study

39

Study: The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis

This study provides evidence supporting the claim.

Contradicts

0 studies

0

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.